北美痛经治疗市场 – 行业趋势及 2028 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

北美痛经治疗市场 – 行业趋势及 2028 年预测

  • Pharmaceutical
  • Published Report
  • Jan 2021
  • North America
  • 350 页面
  • 桌子數: 152
  • 图号: 43

>北美痛经治疗市场,按类型(原发性痛经、继发性痛经)、治疗类型(药物、疗法、手术、其他)、处方方式(非处方、处方)、给药途径(口服、肠胃外、植入物、其他)、最终用户(医院、专科中心、门诊手术中心、其他)、分销渠道(药房、零售、直接招标、其他)、国家(美国、加拿大、墨西哥)划分,行业趋势和预测至 2028 年

北美痛经治疗市场市场分析与洞察:北美痛经治疗市场

预计在 2021 年至 2028 年的预测期内,痛经治疗市场将实现市场增长。Data Bridge Market Research 分析,在 2021 年至 2028 年的预测期内,市场复合年增长率为 7.6%,预计到 2028 年将达到 33.3597 亿美元。痛经等经期健康疾病患病率的上升以及痛经治疗领域的广泛研发活动是预测期内推动市场需求的主要驱动力。

经痛是指身体下腹部痉挛和抽痛。许多女性在月经前后都会出现经痛。对于一些女性来说,经痛很常见,而对于另一些女性来说,经痛很烦人而且很严重,每个月都会有几天影响日常活动。经痛的症状是疼痛,在月经前 1 至 3 天开始,在月经开始后 24 小时达到高峰,2 至 3 天内消退,同时伴有钝痛、持续疼痛、恶心、头痛、头晕、便溏等症状。

痛经治疗的特点包括:对痛经有效治疗的需求不断增长,这将影响制造商向市场推出新产品,从而增加其需求;政府和制药行业不断增加的举措也推动了痛经治疗市场的增长。替代疗法的使用对痛经治疗市场的增长构成了挑战。

目前,正在进行的宣传计划有望为制造商创造竞争优势,以开发新的创新技术。此外,这些宣传计划还有望为月经痉挛治疗市场提供各种其他机会。然而,传统疗法的存在预计将在预测期内抑制月经痉挛治疗市场的增长。

月经痉挛治疗市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息,分析了新兴收入领域、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和月经痉挛治疗市场情况,请联系 Data Ridge Market Research 获取分析师简报,我们的团队将帮助您创建收入影响解决方案,以实现您的预​​期目标。

北美痛经治疗市场北美痛经治疗市场范围和市场规模

月经痉挛治疗市场根据类型、治疗类型、处方方式、给药途径、最终用户和分销渠道进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略,并确定您的核心应用领域和目标市场的差异。

  • 根据类型,痛经治疗市场分为原发性痛经和继发性痛经。2021 年,原发性痛经占据痛经治疗市场的主导地位,因为美国 85% 的女性在月经期间遭受或面临痛经。
  • 根据治疗类型,痛经治疗市场分为药物治疗、疗法、手术和其他治疗。2021 年,药物治疗占据痛经治疗市场的主导地位,因为非甾体抗炎药和复方口服避孕药是痛经的一线治疗方法。
  • 根据处方方式,痛经治疗市场分为处方药和非处方药。2021 年,非处方药在痛经治疗市场占据主导地位,因为大多数药物都是仿制药,药品供应没有任何阻碍,而且通过广告提高了群众的认识。
  • 根据给药途径,痛经治疗市场分为口服、肠外、植入物和其他。2021 年,口服药物占据痛经治疗市场的主导地位,因为口服药物被认为是治疗的第一线药物。此外,口服药物具有更好的患者依从性,这是另一个驱动因素。
  • 根据最终用户,痛经治疗市场分为医院、门诊手术中心、专科中心和其他。2021 年,医院部门在痛经治疗市场占据主导地位,因为大多数患者都经历了更年期症状,因此她们会去医院接受正确的诊断和治疗。
  • 根据分销渠道,痛经治疗市场分为直接招标、零售、药店和其他。2021 年,药店部分在痛经治疗市场占据主导地位,因为药店根据患者的需求提供各种药物。

 月经痉挛治疗市场国家级分析

对痛经治疗市场进行了分析,并按上述国家、类型、治疗类型、处方方式、给药途径、最终用户和分销渠道提供了市场规模信息。

北美痛经治疗市场报告涵盖的国家包括美国、加拿大和墨西哥。

由于北美地区患者大量采用非处方月经痛治疗药物,预计北美处方药市场将占据主导地位。由于该地区主要市场参与者的增加,美国在市场中占据主导地位,并引领北美的增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外,在提供国家数据的预测分析时,还考虑了北美品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。

月经痉挛治疗市场中治疗方案的不断增加为市场参与者创造了新的机会

月经痉挛治疗市场还为您提供每个国家美容行业月经痉挛治疗销售增长的详细市场分析、月经痉挛治疗进步的影响以及监管环境的变化及其对月经痉挛治疗市场的支持。数据涵盖 2010 年至 2019 年的历史时期。

竞争格局和月经痉挛治疗市场份额分析

月经痉挛治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对月经痉挛治疗市场的关注有关。

从事痛经治疗的主要公司包括拜耳公司、葛兰素史克公司、辉瑞公司、Teva Pharmaceuticals USA, Inc.(Teva Pharmaceutical Industries Ltd. 的子公司)、Beurer GmbH、Mylan NV(Viatris Inc. 的一部分)、Boehringer Ingelheim International GmbH、PMS4PMS, LLC、赛诺菲、Nobelpharma Co., Ltd.、ObsEva、Myovant Sciences Ltd.、艾伯维公司、BioElectronics Corporation、Alvogen、Cumberland Pharmaceuticals Inc.、Lupin Pharmaceuticals, Inc.(LUPIN 的子公司)、杨森制药公司(强生服务公司的子公司)、太阳制药工业有限公司以及其他国内和全球公司。DBMR 分析师了解竞争优势并为每个竞争对手分别提供竞争分析。

全球各地的公司也推出了许多产品并达成了多项协议,这也加速了痛经治疗市场的发展。

例如,

  • 2019 年 5 月,PMS4PMS, LLC 宣布推出名为 Comforte 的产品。该产品可在月经期间缓解经期痉挛。该公司推出的这款新产品增加了市场需求和销量。

市场参与者的合作、合资和其他策略正在增强公司在痛经治疗市场的市场,这也为组织改善其在痛经治疗方面的服务提供了好处。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS

4.1 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, PIPELINE ANALYSIS

5 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: REGULATIONS

6 PREMIUM INSIGHTS

6.1 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: ADOPTION RATE

6.1.1 DRIVERS AND BARRIERS FOR THE ADOPTIONS

6.2 MARKETING EXPENSES

6.3 PAYERS:

6.4 PHARMACIES COLD/HOT PADS MARKET SHARE:

7 EPIDEMIOLOGY

8 COVID-19 IMPACT ON NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET

8.1 PRICE IMPACT

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19

8.5 CONCLUSION

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 GROWING PREVALENCE OF DYSMENORRHEA

9.1.2 RISING TECHNOLOGICAL ADVANCEMENTS

9.1.3 INCREASING RESEARCH AND DEVELOPMENT FOR DEVELOPING INNOVATIVE DRUGS AND THERAPIES

9.1.4 GOVERNMENT INITIATIVES WITH RESPECT TO WOMEN HEALTHCARE

9.1.5 INCREASING NUMBER OF TREATMENT OPTIONS

9.2 RESTRAINTS

9.2.1 PRODUCT RECALLS

9.2.2 LACK OF AWARENESS ABOUT REPRODUCTIVE HEALTH IN WOMEN

9.2.3 HIGH COST OF ENDOMETRIAL ABLATION AND HYSTERECTOMY

9.3 OPPORTUNITIES

9.3.1 RISE IN AWARENESS ABOUT DYSMENORRHEA

9.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS

9.3.3 RISING DISPOSABLE INCOME

9.4 CHALLENGES

9.4.1 TRADITIONAL FAMILY VALUE LEADING TO NO TREATMENT

9.4.2 SIDE EFFECTS AND COMPLICATIONS ASSOCIATED WITH LONG TERM TREATMENT

9.4.3 EFFECTIVENESS OF COMPLEMENTARY AND ALTERNATIVE THERAPIES

10 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE

10.1 OVERVIEW

10.2 PRIMARY DYSMENORRHEA

10.3 SECONDARY DYSMENORRHEA

11 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE

11.1 OVERVIEW

11.2 MEDICATION

11.2.1 FIRST LINE TREATMENT

11.2.1.1 Nonhormonal Therapy

11.2.1.1.1 Nonsteroidal Anti-Inflammatory Drugs

11.2.1.1.1.1 Ibuprofen

11.2.1.1.1.2 Naproxen

11.2.1.1.1.3 Celecoxib

11.2.1.1.1.4 Mefenamic Acid

11.2.1.1.1.5 Meclofenamate

11.2.1.1.2 Acetaminophen

11.2.1.2 Hormonal Replacement Therapy y

11.2.1.2.1 Combined Oral Contraceptives (Monophasic or Multiphasic)

11.2.1.2.1.1 Norethindrone/Ethinyl Estradiol

11.2.1.2.1.2 Extended-Cycle Oral Contraceptives

11.2.1.2.2 Extended-Cycle Oral Contraceptives

11.2.1.2.2.1 Levonorgestrel/Ethinyl Estradiol

11.2.1.2.2.2 Others

11.2.1.2.3 Other

11.2.1.2.3.1 Etonogestrel/Ethinyl Estradiol

11.2.1.2.3.2 Etonogestrel Implant

11.2.1.2.3.3 Levonorgestrel-Releasing Intrauterine System

11.2.1.2.3.4 Medroxyprogesterone Shot

11.2.1.3 Diuretic

11.2.1.3.1 Spironolactone

11.2.1.3.2 Ammonium Chloride

11.2.1.4 Antidepressants

11.2.2 SECOND LINE TREATMENT

11.2.2.1 Empiric GNRH Analogue or Antagonist Therapy

11.2.2.2 Ammonium Chloride

11.3 THERAPY

11.3.1 HEAT THERAPY

11.3.1.1 Patch

11.3.1.2 Wrap

11.3.1.3 Ceramic Belt Emitting Far-Infrared Radiation (FIR)

11.3.2 BEHAVIORAL COUNSELING

11.3.2.1 Desensitization-Based Procedures

11.3.2.2 Coping Strategies

11.3.2.3 Imagery

11.3.2.4 Hypnotherapy

11.3.2.5 Others

11.3.3 DIET AND VITAMINS

11.3.3.1 Vitamin E

11.3.3.2 Vitamin B

11.3.3.3 Vitamin D

11.3.3.4 Others

11.4 SURGERY

11.4.1 ENDOMETRIAL ABLATION

11.4.2 HYSTERECTOMY

11.5 OTHERS

12 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION

12.1 OVERVIEW

12.2 OVER THE COUNTER

12.3 PRESCRIPTION

13 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 ORAL

13.2.1 TABLETS

13.2.2 PILLS

13.2.3 CAPSULE

13.2.4 OTHERS

13.3 PARENTERAL

13.3.1 INTRAVENOUS

13.3.2 SUBCUTANEOUS

13.3.3 OTHERS

13.4 IMPLANTS

13.5 OTHERS

14 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 SPECIALTY CENTERS

14.4 AMBULATORY SURGICAL CENTERS

14.5 OTHERS

15 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 PHARMACIES

15.2.1 HOSPITAL

15.2.2 RETAIL

15.3 DIRECT TENDER

15.4 RETAIL SALES

15.5 OTHERS

16 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY GEOGRAPHY

16.1 NORTH AMERICA

16.1.1 U.S

16.1.2 CANADA

16.1.3 MEXICO

17 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 GLAXOSMITHKLINE PLC.

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENTS

19.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENT

19.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANLYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENTS

19.4 ABBVIE INC.

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENTS

19.5 MYLAN N. V. (A PART OF VIATRIS INC.).

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 PRODUCT PORTFOLIO

19.5.4 RECENT DEVELOPMENT

19.6 ALVOGEN

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 BAYER AG

19.7.1 COMPANY SNAPSHOT

19.7.2 REVENUE ANALYSIS

19.7.3 PRODUCT PORTFOLIO

19.7.4 RECENT DEVELOPMENTS

19.8 BEURER GMBH

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENT

19.9 BIOELECTRONICS CORPORATION

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENT

19.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 COLOR SEVEN CO., LTD.

19.11.1 COMPANY SNAPSHOT

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENTS

19.12 CUMBERLAND PHARMACEUTICALS INC.

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENTS

19.13 LIVIA

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENTS

19.14 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)

19.14.1 COMPANY SNAPSHOT

19.14.2 REVENUE ANALYSIS

19.14.3 PRODUCT PORTFOLIO

19.14.4 RECENT DEVELOPMENTS

19.15 MYOVANT SCIENCES LTD.

19.15.1 COMPANY SNAPSHOT

19.15.2 PRODUCT PORTFOLIO

19.15.3 RECENT DEVELOPMENT

19.16 NOBELPHARMA CO., LTD.

19.16.1 COMPANY SNAPSHOT

19.16.2 REVENUE ANALYSIS

19.16.3 PRODUCT PORTFOLIO

19.16.4 RECENT DEVELOPMENT

19.17 OBSEVA

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENTS

19.18 PFIZER INC.

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENTS

19.19 PMS4PMS, LLC

19.19.1 COMPANY SNAPSHOT

19.19.2 PRODUCT PORTFOLIO

19.19.3 RECENT DEVELOPMENT

19.2 SANOFI

19.20.1 COMPANY SNAPSHOT

19.20.2 REVENUE ANALYSIS

19.20.3 PRODUCT PORTFOLIO

19.20.4 RECENT DEVELOPMENT

19.21 SUN PHARMACEUTICAL INDUSTRIES LTD.

19.21.1 COMPANY SNAPSHOT

19.21.2 REVENUE ANALYSIS

19.21.3 PRODUCT PORTFOLIO

19.21.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

表格列表

LIST OF TABLES

TABLE 1 MARKETING EXPENSES OF THE MARKET PLAYERS

TABLE 2 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 3 NORTH AMERICA PRIMARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 NORTH AMERICA SECONDARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 6 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 7 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 8 NORTH AMERICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 NORTH AMERICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 10 NORTH AMERICA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 11 NORTH AMERICA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 12 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 13 NORTH AMERICA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 14 NORTH AMERICA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 15 NORTH AMERICA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 16 NORTH AMERICA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 17 NORTH AMERICA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 18 NORTH AMERICA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 19 NORTH AMERICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 NORTH AMERICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 21 NORTH AMERICA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 22 NORTH AMERICA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 23 NORTH AMERICA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 24 NORTH AMERICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 NORTH AMERICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 26 NORTH AMERICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 28 NORTH AMERICA OVER THE COUNTER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 NORTH AMERICA PRESCRIPTION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 NORTH AMERICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 33 NORTH AMERICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 NORTH AMERICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 35 NORTH AMERICA IMPLANTS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 NORTH AMERICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2020-2028 (USD MILLION)

TABLE 38 NORTH AMERICA HOSPITALS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 NORTH AMERICA SPECIALTY CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 41 NORTH AMERICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

TABLE 43 NORTH AMERICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 NORTH AMERICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 45 NORTH AMERICA DIRECT TENDER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 NORTH AMERICA RETAIL SALES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 47 NORTH AMERICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 48 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 49 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 50 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 51 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 52 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 53 NORTH AMERICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 54 NORTH AMERICA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 55 NORTH AMERICA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 56 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 57 NORTH AMERICA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 58 NORTH AMERICA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 59 NORTH AMERICA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 60 NORTH AMERICA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 61 NORTH AMERICA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 62 NORTH AMERICA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 63 NORTH AMERICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 64 NORTH AMERICA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 65 NORTH AMERICA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 66 NORTH AMERICA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 67 NORTH AMERICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 68 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 69 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 70 NORTH AMERICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 71 NORTH AMERICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 72 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 73 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 74 NORTH AMERICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 75 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 76 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 77 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 78 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 79 U.S. MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 80 U.S. FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 81 U.S. NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 82 U.S. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 83 U.S. HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 84 U.S. COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 85 U.S. EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 86 U.S. OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 87 U.S. DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 88 U.S. SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 89 U.S. THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 90 U.S. HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 91 U.S. BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 92 U.S. DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 93 U.S. SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 94 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 95 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 96 U.S. ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 97 U.S. PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 98 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 99 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 100 U.S. PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 101 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 102 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 103 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 104 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 105 CANADA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 106 CANADA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 107 CANADA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 108 CANADA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 109 CANADA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 110 CANADA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 111 CANADA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 112 CANADA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 113 CANADA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 114 CANADA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 115 CANADA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 116 CANADA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 117 CANADA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 118 CANADA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 119 CANADA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 120 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 121 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 122 CANADA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 123 CANADA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 124 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 125 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 126 CANADA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 127 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 128 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 129 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 130 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 131 MEXICO MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 132 MEXICO FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 133 MEXICO NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 134 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 135 MEXICO HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 136 MEXICO COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 137 MEXICO EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 138 MEXICO OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 139 MEXICO DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 140 MEXICO SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 141 MEXICO THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 142 MEXICO HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 143 MEXICO BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 144 MEXICO DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 145 MEXICO SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 146 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 147 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 148 MEXICO ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 149 MEXICO PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 150 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 151 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 152 MEXICO PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

 

图片列表

LIST OF FIGURES

FIGURE 1 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 10 INCREASING PREVALENCE OF DYSMENORRHEA IS EXPECTED TO DRIVE THE NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 11 PRIMARY DYSMENORRHEA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET IN 2021 & 2028

FIGURE 12 PHARMACIES COLD/HOT PADS MARKET SHARE: 2020 (%)

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET

FIGURE 14 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020

FIGURE 15 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)

FIGURE 16 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 17 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020

FIGURE 19 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020-2028 (USD MILLION)

FIGURE 20 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2021-2028)

FIGURE 21 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 22 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, 2020

FIGURE 23 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION 2020-2028 (USD MILLION)

FIGURE 24 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, CAGR (2021-2028)

FIGURE 25 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, LIFELINE CURVE

FIGURE 26 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 27 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)

FIGURE 28 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 29 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 30 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020

FIGURE 31 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 32 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, CAGR (2021-2028)

FIGURE 33 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 35 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 36 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 37 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: SNAPSHOT (2020)

FIGURE 39 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020)

FIGURE 40 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2021 & 2028)

FIGURE 41 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020 & 2028)

FIGURE 42 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE (2021-2028)

FIGURE 43 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY SHARE 2020 (%)

 

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.